Immune reconstitution in human immunodeficiency virus type 1-infected children with different virological responses to anti-retroviral therapy

Clinical and Experimental Immunology

Volumn 150, Issue 3, 2007, Pages 442-450

  Anselmi, A ^a   Vendrame, D ^a   Rampon, O ^a   Giaquinto, C ^a   Zanchetta, M ^a   De Rossi, A ^a,b  

^a UNIVERSITY OF PADOVA   (Italy)

^b AIDS Reference Center   (Italy)

Author keywords

HAART; HIV 1 infected children; Immune reconstitution; LPS; T cell activation

Indexed keywords

CD38 ANTIGEN; INDINAVIR; LAMIVUDINE PLUS NEVIRAPINE PLUS STAVUDINE; LAMIVUDINE PLUS NEVIRAPINE PLUS ZIDOVUDINE; LIPOPOLYSACCHARIDE; NELFINAVIR; RITONAVIR; T LYMPHOCYTE RECEPTOR;

ADOLESCENT; ARTICLE; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CELLULAR IMMUNITY; CHILD; CLINICAL ARTICLE; CONTROLLED STUDY; EFFECTOR CELL; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS 1 INFECTION; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; IMMUNE RESPONSE; LYMPHOCYTE COUNT; MEMORY T LYMPHOCYTE; PRIORITY JOURNAL; T LYMPHOCYTE ACTIVATION; T LYMPHOCYTE SUBPOPULATION; TREATMENT DURATION; TREATMENT RESPONSE; VIREMIA;

ADOLESCENT; ANTI-HIV AGENTS; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; CD4 LYMPHOCYTE COUNT; CHILD; CHILD, PRESCHOOL; FOLLOW-UP STUDIES; GENE REARRANGEMENT, T-LYMPHOCYTE; HIV INFECTIONS; HIV-1; HUMANS; LIPOPOLYSACCHARIDES; LYMPHOCYTE ACTIVATION; T-LYMPHOCYTE SUBSETS; VIRAL LOAD; VIREMIA;

EID: 36048957163     PISSN: 00099104     EISSN: 13652249     Source Type: Journal    
DOI: 10.1111/j.1365-2249.2007.03526.x     Document Type: Article

References (43)

1. De Rossi A, Masiero S, Giaquinto C et al. Dynamics of viral replication in infants with vertically acquired human immunodeficiency virus type 1 infection. J Clin Invest 1996 97 : 323 30.
2. Luzuriaga K, Wu H, McManus M et al. Dynamics of human immunodeficiency virus type 1 replication in vertically infected infants. J Virol 1999 73 : 362 7.
3. Giorgi JV, Hultin LE, McKeating JA et al. Shorter survival in advanced human immunodeficiency virus type 1 infection is more closely associated with T lymphocyte activation than with plasma virus burden or virus chemokine coreceptor usage. J Infect Dis 1999 179 : 859 70.
4. Sankaran S, Guadalupe M, Reay E et al. Gut mucosal T cell responses and gene expression correlate with protection against disease in long-term HIV-1-infected nonprogressors. Proc Natl Acad Sci USA 2005 102 : 9860 5.
5. Valdez H, Lederman MM. Cytokines and cytokine therapies in HIV infection. AIDS Clin Rev 1997 1998 : 187 228.
6. Behbahani H, Walther-Jallow L, Klareskog E et al. Proinflammatory and type 1 cytokine expression in cervical mucosa during HIV-1 and human papillomavirus infection. J Acquir Immune Defic Syndr 2007 45 : 9 19.
7. Brenchley JM, Price DA, Schacker TW et al. Microbial translocation is a cause of systemic immune activation in chronic HIV infection. Nat Med 2006 12 : 1365 71.
8. Mehandru S, Poles MA, Tenner-Racz K et al. Primary HIV-1 infection is associated with preferential depletion of CD4+ T lymphocytes from effector sites in the gastrointestinal tract. J Exp Med 2004 200 : 761 70.
9. Purswani M, Johann-Liang R, Cervia J, Noel GJ. Effect of changing antiretroviral therapy on human immunodeficiency virus viral load: experience with fifty-four perinatally infected children. Pediatr Infect Dis J 1999 18 : 512 6.
10. Gibb DM, Newberry A, Klein N, De Rossi A, Grosch-Woerner I, Babiker A. Immune repopulation after HAART in previously untreated HIV-1-infected children. Paediatric European Network for Treatment of AIDS (PENTA) Steering Committee. Lancet 2000 355 : 1331 2.
11. + T cell response to HIV-1. Curr Opin Immunol 2000 12 : 381 6.
12. Lederman MM, Valdez H. Immune restoration with antiretroviral therapies. JAMA 2000 284 : 223 8.
13. Pakker NG, Notermans DW, De Boer RJ et al. Biphasic kinetics of peripheral blood T cells after triple combination therapy in HIV-1 infection: a composite of redistribution and proliferation. Nat Med 1998 4 : 208 14.
14. Kaufmann GR, Zaunders J, Murray J et al. Relative significance of different pathways of immune reconstitution in HIV type 1 infection as estimated by mathematical modeling. AIDS Res Hum Retroviruses 2001 17 : 147 59.
15. Ometto L, De Forni D, Patiri F et al. Immune reconstitution in HIV-1-infected children on antiretroviral therapy: role of thymic output and viral fitness. AIDS 2002 16 : 839 49.
16. De Rossi A, Walker AS, Klein N, De Forni D, King D, Gibb DM. Increased thimic output after initiation of antiretroviral therapy in human immunodeficiency virus type 1-infected children in the Paediatric European Network for treatment of AIDS (PENTA) 5 trial. J Infect Dis 2002 186 : 312 20.
17. Resino S, Galan I, Bellon JM, Navarro ML, Leon JA, Munoz-Fernandez MA. Characterizing the immune system after long-term undetectable viral load in HIV-1-infected children. J Clin Immunol 2003 23 : 279 89.
18. Fraaij PL, Verweel G, Van Rossum AM et al. Sustained viral suppression and immune recovery in HIV type 1-infected children after 4 years of highly active antiretroviral therapy. Clin Infect Dis 2005 40 : 604 8.
19. Chavan S, Bennuri B, Kharbanda M, Chandrasekaran A, Bakshi S, Pahwa S. Evaluation of T cell receptor gene rearrangement excision circles after antiretroviral therapy in children infected with human immunodeficiency virus. J Infect Dis 2001 183 : 1445 54.
20. Bagnarelli P, Vecchi M, Burighel N et al. Genotypic and phenotypic correlates of the HIV type 1 env gene evolution in infected children with discordant response to antiretroviral therapy. AIDS Res Hum Retroviruses 2004 20 : 1306 13.
21. Resino S, Galan I, Perez A et al. HIV-infected children with moderate/severe immune-suppression: changes in the immune system after highly active antiretroviral therapy. Clin Exp Immunol 2004 137 : 570 7.
22. Ghaffari G, Passalacqua DJ, Caicedo JL, Goodenow MM, Sleasman JW. Two-year clinical and immune outcomes in human immunodeficiency virus-infected children who reconstitute CD4 T cells without control of viral replication after combination antiretroviral therapy. Pediatrics 2004 114 : 604 11.
23. + T cells in human immunodeficiency virus-infected patients experiencing virologic treatment failure. Role of changes in thymic output and T cell death. J Infect Dis 2001 183 : 1009 16.
24. Stoddart CA, Liegler TJ, Mammano F et al. Impaired replication of protease inhibitor-resistant HIV-1 in human thymus. Nat Med 2001 7 : 712 8.
25. Hunt P, Deeks S, Bangsberg D et al. The independent effect of drug resistance on T cell activation in HIV infection. AIDS 2006 20 : 691 9.
26. + T-cell maturation: CD27 might provide a clue. Trends Immunol 2002 23 : 586 91.
27. + memory T cells define a differentiated memory population at both the functional and transcriptional levels. Immunology 2004 113 : 363 70.
28. - T cells in HIV-1-infected children. AIDS 2005 19 : 1025 34.
29. Sallusto F, Geginat J, Lanzavecchia A. Central memory and effector memory T cell subsets: function, generation, and maintenance. Annu Rev Immunol 2004 22 : 745 63.
30. Emu B, Sinclair E, Favre D et al. Phenotypic, functional, and kinetic parameters associated with apparent T cell control of human immunodeficiency virus replication in individuals with and without antiretroviral treatment. J Virol 2005 79 : 14169 78.
31. Jordan KA, Furlan SN, Gonzalez VD et al. CD8 T cell effector maturation in HIV-1-infected children. Virology 2006 347 : 117 26.
32. Brenchley JM, Douek DC, Ambrozak DR et al. Expansion of activated human naive T-cells precedes effector function. Clin Exp Immunol 2002 130 : 432 40.
33. Wang YM, Wang B, Dyer WB, Lachireddy K, Peng NK, Saksena NK. Evidence for predominance of CCR5-using HIV-1 strains during highly active antiretroviral therapy. Curr HIV Res 2007 5 : 221 34.
34. Brenchley JM, Hill BJ, Ambrozak DR et al. T-cell subsets that harbor human immunodeficiency virus (HIV) in vivo: implications for HIV pathogenesis. J Virol 2004 78 : 1160 8.
35. Ye P, Kirschner DE, Kourtis AP. The thymus during HIV disease: role in pathogenesis and in immune recovery. Curr HIV Res 2004 2 : 177 83.
36. Mammano F, Trouplin V, Zennou V, Clavel F. Retracing the evolutionary pathways of human immunodeficiency virus type 1 resistance to protease inhibitors: virus fitness in the absence and in the presence of drug. J Virol 2000 74 : 8524 31.
37. Savarino A, Bottarel F, Malavasi F, Dianzani U. Role of CD38in HIV-1 infection: an epiphenomenon of T-cell activation or an active player in virus/host interactions? AIDS 2000 14 : 1079 89.
38. Resino S, Seoane E, Gutierrez MD, León JA, Muñoz- Fernández MA. CD4+ T-cell immunodeficiency is more dependent on immune activation than viral load in HIV-infected children on highly active antiretroviral therapy. J Acquir Immune Defic Syndr 2006 42 : 269 76.
39. De Martino M, Rossi ME, Azzari C, Gelli MG, Galli L, Vierucci A. Different meaning of CD38 molecule expression on CD4+ and CD8+ cells of children perinatally infected with human immunodeficiency virus type 1 infection surviving longer than five years. Pediatr Res 1998 43 : 752 8.
40. De Vries E, De Bruin-Versteeg S, Comans-Bitter WM et al. Longitudinal survey of lymphocyte subpopulations in the first year of life. Pediatr Res 2000 47 : 528 37.
41. McCune JM. The dynamics of CD4+ T-cell depletion in HIV disease. Nature 2001 410 : 974 9.
42. Douek DC, Brenchley JM, Betts MR et al. HIV preferentially infects HIV-specific CD4+ T cells. Nature 2002 417 : 95 8.
43. Rosenblatt H, Stanley K, Song L et al. Immunological response to highly active antiretroviral therapy in children with clinically stable HIV-1 infection. J Infect Dis 2005 192 : 445 55.